Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products
2 Assignments
0 Petitions
Accused Products
Abstract
Novel polypeptides having anti-apoptotic activity, and methods of screening for such novel polypeptides having anti-apoptotic activity, and polynucleotides encoding such polypeptides; Compounds that regulate or modulate apoptosis and/or anti-apoptotic activity, such as compounds having anti-apoptotic activity, and such as compounds that induce, restore, or modulate apoptosis and/or inhibit, diminish, or modulate anti-apoptotic activity, methods of screening for such compounds, and methods of using such compounds in the therapeutic treatment of diseases; Methods of treating eukaryotic cells with compounds that regulate or modulate apoptosis and/or anti-apoptotic activity; Methods of enhancing the stability, growth, and/or productivity of eukaryotic cells; Pharmaceutical compositions that regulate or modulate apoptosis and/or anti-apoptotic activity.
13 Citations
134 Claims
-
1-100. -100. (canceled)
-
101. A method for modulating apoptosis in a eukaryotic cell, said method comprising:
- contacting a eukaryotic cell with an effective amount of an agent, wherein said agent is selected from the group consisting of;
(a) a polynucleotide which encodes human cytomegalovirus polypeptide pUL37S, (b) a fragment of (a) having anti-apoptotic activity, (c) a homologue of (a) or (b) having anti-apoptotic activity, (d) human cytomegalovirus polypeptide pUL37S, (e) a fragment of (d) having anti-apoptotic activity, (f) a homologue of (d) or (e) having anti-apoptotic activity, and (g) a compound which binds to said polynucleotide (a) or said polypeptide (d), and wherein said modulation is an inhibition, diminution, restoration or induction of apoptosis, thereby modulating apoptosis in a eukaryotic cell. - View Dependent Claims (102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127)
- contacting a eukaryotic cell with an effective amount of an agent, wherein said agent is selected from the group consisting of;
-
128. A composition comprising a therapeutically effective amount of an agent, wherein said agent is selected from the group consisting of:
-
(a) a polynucleotide which encodes human cytomegalovirus polypeptide pUL37S, (b) a fragment of (a) having anti-apoptotic activity, (c) a homologue of (a) or (b) having anti-apoptotic activity, (d) human cytomegalovirus polypeptide pUL37S, (e) a fragment of (d) having anti-apoptotic activity, (f) a homologue of (d) or (e) having anti-apoptotic activity, and (g) a compound which binds to polynucleotide (a) or polypeptide (d), and wherein said modulation is an inhibition, diminution, restoration or induction of apoptosis wherein the therapeutically effective amount is an amount that modulates apoptotic activity. - View Dependent Claims (129, 130, 131, 132, 133)
-
-
134. A pharmaceutical composition comprising a therapeutically effective amount of an agent and a pharmaceutically-acceptable carrier or excipient, wherein said agent is selected from the group consisting of:
-
(a) a polynucleotide which encodes human cytomegalovirus polypeptide pUL37S, (b) a fragment of (a) having anti-apoptotic activity, (c) a homologue of (a) or (b) having anti-apoptotic activity, (d) human cytomegalovirus polypeptide pUL37S, (e) a fragment of (d) having anti-apoptotic activity, (f) a homologue of (d) or (e) having anti-apoptotic activity, and (g) a compound which binds to polynucleotide (a) or polypeptide (d), and wherein said modulation is an inhibition, diminution, restoration or induction of apoptosis wherein the therapeutically effective amount is an amount that modulates apoptotic activity.
-
Specification